New Ask Claude or ChatGPT about any stock, using Bullpen. Bullpen in Claude or ChatGPT. 7 days free

Friday, November 13, 2026

Back to the front page

Nvidia’s Future | My Question Marks

Nvidia’s future is framed around alleged China GPU diversion, tighter export controls and supply-chain risk after Jensen Huang’s claimed resignation.

From X

Serenity on X

I found the technical discussion helpful, but investor messaging to be way too conservative. If you look at how $NVDA CEO describes CPO, Jensen states scale up is increasing optical volumes by 15x. $LITE and $COHR are quantifying that by describing $5-$20B agreements spanning 3-5 years out. Having this question, and not talking about Ayar, O-Net, Poet, or ELS partnerships. Then redirecting the question to near term pluggables seems off. The vision also needs work, “communications and sensing” semi company is very unexciting. It’s technically true, but there’s no vision being communicated on being the next $40B optical giant or what Sivers is going to be in the next 5 years that would attract long term holders. The core valuation Sivers gets is from optical opportunities, I also personally disagree that it’s helpful to loop back to former cellular relationships when talking about future $GFS volumes I disagree when you portray the company as “small” when Sivers 100m CW DFB capacity is coming online, alongside large foundry partners. Which is a material % of the world’s annual laser capacity. Investors want to hear about future economic opportunities and how you fill the gap with more qualifications during a bottleneck. Sivers has a tremendous opportunity for CPO/NPO/Pluggables but I’m afraid it’s not being communicated properly. It’s understandable here since EETimes is more technical oriented, but I hope this messaging gets communicated better in the next earnings call.

QXO Inc Earnings Update: Q3 2026

QXO's Q3 sales rose 79% to $4.9 billion after TopBuild and Kodiak acquisitions, while acquisition debt lifted interest expense to $163…

Qure Anniversary Update

UniQure’s Huntington’s disease BLA has a May 1, 2027 priority-review date, with an FDA advisory committee expected in late first quarter.

Big Short: Fidelity & Guaranty

F&G’s main insurer held $66.5 billion of assets against $1.38 billion of statutory capital, while private credit, reinsurance dependence…

Publications we follow

Every publication on this site, hand-picked.

130 publications

Newsletters 110

X accounts we follow

Every account on this site, hand-picked.

91 accounts

Investor letters we follow

376 firms

Sectors

Ordered by how often our editor reaches for them.